<p>India's drug regulator said on Monday that Johnson & Johnson withdrew its proposal seeking accelerated approval of its Covid-19 vaccine in the country, without giving additional details.</p>.<p>The US-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen Covid-19 vaccine candidate in India. Trials in the United States at that time were paused on reports of rare blood clots.</p>.<p><strong>Also Read — <a href="https://www.deccanherald.com/business/business-news/johnson-johnson-forecasts-25-billion-in-2021-covid-vaccine-sales-1011146.html" target="_blank">Johnson & Johnson forecasts $2.5 billion in 2021 Covid vaccine sales</a></strong></p>.<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>.<p>"This team is in continuous dialogue with Pfizer, Moderna and Johnson & Johnson to discuss and address various issues including the issue of indemnity," Bharati Pravin Pawar had said.</p>.<p>Johnson & Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to <em>Reuters</em>' requests for comments on why the company withdrew its application.</p>.<p>As of July 31, Johnson & Johnson is yet to request a full approval for its shot with the US FDA, while Pfizer Inc, BioNTech SE, and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>.<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June. </p>
<p>India's drug regulator said on Monday that Johnson & Johnson withdrew its proposal seeking accelerated approval of its Covid-19 vaccine in the country, without giving additional details.</p>.<p>The US-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen Covid-19 vaccine candidate in India. Trials in the United States at that time were paused on reports of rare blood clots.</p>.<p><strong>Also Read — <a href="https://www.deccanherald.com/business/business-news/johnson-johnson-forecasts-25-billion-in-2021-covid-vaccine-sales-1011146.html" target="_blank">Johnson & Johnson forecasts $2.5 billion in 2021 Covid vaccine sales</a></strong></p>.<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>.<p>"This team is in continuous dialogue with Pfizer, Moderna and Johnson & Johnson to discuss and address various issues including the issue of indemnity," Bharati Pravin Pawar had said.</p>.<p>Johnson & Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to <em>Reuters</em>' requests for comments on why the company withdrew its application.</p>.<p>As of July 31, Johnson & Johnson is yet to request a full approval for its shot with the US FDA, while Pfizer Inc, BioNTech SE, and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>.<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June. </p>